BRAF and melanoma: Instead, full length CSPG4 and BRAF-V600E both appear to be required for sustained Erk 1,2 activation (193) and a CSPG4-specific mAb enhanced and increased the duration of the effects of a BRAF inhibitor in melanoma cells (194).